Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
💎 Reveal Undervalued Stocks Hiding in Any Market Get Started
Close

Genmab (GMAB)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
2,604.0 +26.0    +1.01%
15:59:51 - Closed. Currency in DKK ( Disclaimer )
  • Volume: 90,825
  • Bid/Ask: 0.0 / 0.0
  • Day's Range: 2,592.0 - 2,624.0
Type:  Equity
Market:  Denmark
ISIN:  DK0010272202 
S/N:  65985932
Genmab 2,604.0 +26.0 +1.01%

GMAB Income Statement

 
Assess the Genmab income statement, view the company's financial performance across their assets and liabilities. Select to view either quarterly or annual data.
AnnualQuarterly
InvestingPro Advanced Income Statement
Collapse All
Period Ending: 2022
31/12
 2022
30/09
 2022
30/06
 2022
31/03
Total Revenue 5227 4087 3162 2119
Revenue 5227 4087 3162 2119
Other Revenue, Total - - - -
Cost of Revenue, Total - - - -
Gross Profit 5227 4087 3162 2119
Total Operating Expenses 2524 2156 1915 1605
Selling/General/Admin. Expenses, Total 921 670 633 452
Research & Development 1603 1486 1282 1153
Depreciation / Amortization 254 - - -
Interest Expense (Income) - Net Operating -3108 -6 -200 -4
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 2854 6 200 4
Operating Income 2703 1931 1247 514
Interest Income (Expense), Net Non-Operating - - - 98
Gain (Loss) on Sale of Assets -659 -206 - -335
Other, Net 2700 -1135 -1242 237
Net Income Before Taxes 662 3272 2489 612
Provision for Income Taxes 78 690 598 147
Net Income After Taxes 584 2582 1891 465
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 584 2582 1891 465
Total Extraordinary Items - - - -
Net Income 584 2582 1891 465
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 584 2582 1891 465
Dilution Adjustment 0.297 - - -
Diluted Net Income 583.7 2582 1891 465
Diluted Weighted Average Shares 66.07 65.92 65.98 65.96
Diluted EPS Excluding Extraordinary Items 8.83 39.17 28.66 7.05
DPS - Common Stock Primary Issue - - - -
Diluted Normalized EPS 12.86 32.98 23.58 8.97
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

GMAB Comments

Write your thoughts about Genmab
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email